{
    "clinical_study": {
        "@rank": "21713", 
        "arm_group": [
            {
                "arm_group_label": "PUR0200 low dose", 
                "arm_group_type": "Experimental", 
                "description": "PUR0200 low dose, single dose inhalation"
            }, 
            {
                "arm_group_label": "PUR0200 mid dose", 
                "arm_group_type": "Experimental", 
                "description": "PUR0200 mid dose, single dose inhalation"
            }, 
            {
                "arm_group_label": "PUR0200 high dose", 
                "arm_group_type": "Experimental", 
                "description": "PUR0200 high dose, single dose inhalation"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "PUR0200 matched placebo, single dose, inhalation"
            }, 
            {
                "arm_group_label": "Active Comparator", 
                "arm_group_type": "Active Comparator", 
                "description": "Active Comparator, single dose, inhalation"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the safety and tolerability of PUR0200. In addition,\n      the study will look at the blood levels of different doses of PUR0200 and their affect on\n      lung function in COPD patients."
        }, 
        "brief_title": "A Safety, Pharmacokinetic and Pharmacodynamic Study of PUR0200 in COPD Patients", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Obstructive Pulmonary Disease (COPD)", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a multi-center, 2-part, pharmacokinetic (PK), pharmacodynamic (PD) effect, safety\n      and tolerability study of single doses of PUR0200."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  A clinical diagnosis of moderate to severe COPD according to the following criteria:\n\n               -  Current or ex-smokers with at least 10 pack-year smoking history\n\n               -  Post-bronchodilator FEV1 >/= 35% and </= 80% of predicted normal value\n\n               -  Post-bronchodilator FEV1/FVC (forced vital capacity) ratio <0.70\n\n               -  Post-bronchodilator improvement in FEV1 >/= 100 mL\n\n        Key Exclusion Criteria:\n\n          -  Current evidence or recent history of clinically significant or unstable   disease\n             (other than COPD)\n\n          -  Current diagnosis of asthma\n\n          -  Presence of history of clinically significant allergy requiring treatment\n\n          -  COPD exacerbation within 6 weeks\n\n          -  Use of daily oxygen therapy > 10 hours\n\n          -  Thoracotomy with pulmonary resection\n\n          -  Use of systemic steroids within 3 months\n\n          -  Lower respiratory tract infection within 30 days\n\n          -  Upper respiratory tract infection within 30 days requiring treatment with antibiotics\n\n          -  History of tuberculosis, bronchiectasis, or other non-specific pulmonary disease\n\n          -  Prolonged corrected QT (QTc) interval >450 msec males and >470 msec females, or\n             history of long QT syndrome"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "38", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01921712", 
            "org_study_id": "601-0010P"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "PUR0200 low dose", 
                    "PUR0200 mid dose", 
                    "PUR0200 high dose"
                ], 
                "description": "Randomized single doses of 3 selected doses of PUR0200, compared to a placebo and active comparator", 
                "intervention_name": "PUR0200", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Randomized, single dose of inhaled placebo matched to PUR0200", 
                "intervention_name": "PUR0200 Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Active Comparator", 
                "description": "Randomized single dose of inhaled active comparator product", 
                "intervention_name": "Active comparator", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "COPD", 
            "Chronic Obstructive Pulmonary Disease"
        ], 
        "lastchanged_date": "March 17, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom", 
                        "zip": "M23 9QZ"
                    }, 
                    "name": "Medicines Evaluation Unit"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nottingham", 
                        "country": "United Kingdom", 
                        "zip": "NG11 6JS"
                    }, 
                    "name": "Quotient Clinical"
                }
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "5", 
        "official_title": "A Phase I, 2-Part, Single-dose, Placebo and Active-Controlled, Dose-ranging, Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability in Subjects With Chronic Obstructive Pulmonary Disease (COPD)", 
        "overall_official": {
            "affiliation": "Pulmatrix Inc.", 
            "last_name": "David Hava, Ph.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Peak plasma concentration (Cmax) of PUR0200", 
                "safety_issue": "No", 
                "time_frame": "0 to 24 hours"
            }, 
            {
                "measure": "Time to reach peak plasma (Tmax) concentration of PUR0200", 
                "safety_issue": "No", 
                "time_frame": "0 to 24 hours"
            }, 
            {
                "measure": "Area under the plasma concentration versus time (AUC) of PUR0200", 
                "safety_issue": "No", 
                "time_frame": "0 to 24 hours"
            }, 
            {
                "measure": "Trough forced expiratory volume in 1 second (FEV1)", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "measure": "Trough FEV1 difference from baseline", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "description": "adverse events, vital signs, clinical laboratory changes, and ECG changes will be evaluated", 
                "measure": "Number of participants with adverse events", 
                "safety_issue": "No", 
                "time_frame": "up to 14 days post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01921712"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Pulmatrix Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Quotient Clinical", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Pulmatrix Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}